BONE BIOLOGICS CORP (BBLG) Fundamental Analysis & Valuation

NASDAQ:BBLG • US0980706008

1.22 USD
-0.03 (-2.4%)
Last: Mar 5, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BBLG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BBLG. BBLG was compared to 520 industry peers in the Biotechnology industry. While BBLG has a great health rating, there are worries on its profitability. BBLG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. BBLG Profitability Analysis

1.1 Basic Checks

  • In the past year BBLG has reported negative net income.
  • In the past year BBLG has reported a negative cash flow from operations.
  • BBLG had negative earnings in each of the past 5 years.
  • BBLG had a negative operating cash flow in each of the past 5 years.
BBLG Yearly Net Income VS EBIT VS OCF VS FCFBBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of BBLG (-62.13%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -65.59%, BBLG is in line with its industry, outperforming 57.12% of the companies in the same industry.
Industry RankSector Rank
ROA -62.13%
ROE -65.59%
ROIC N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLG Yearly ROA, ROE, ROICBBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K -10K

1.3 Margins

  • BBLG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLG Yearly Profit, Operating, Gross MarginsBBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BBLG Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBLG Yearly Shares OutstandingBBLG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
BBLG Yearly Total Debt VS Total AssetsBBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -16.21, we must say that BBLG is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BBLG (-16.21) is worse than 80.96% of its industry peers.
  • There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.21
ROIC/WACCN/A
WACCN/A
BBLG Yearly LT Debt VS Equity VS FCFBBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • A Current Ratio of 19.00 indicates that BBLG has no problem at all paying its short term obligations.
  • BBLG has a Current ratio of 19.00. This is amongst the best in the industry. BBLG outperforms 95.58% of its industry peers.
  • BBLG has a Quick Ratio of 19.00. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of BBLG (19.00) is better than 95.58% of its industry peers.
Industry RankSector Rank
Current Ratio 19
Quick Ratio 19
BBLG Yearly Current Assets VS Current LiabilitesBBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BBLG Growth Analysis

3.1 Past

  • BBLG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.38%, which is quite impressive.
EPS 1Y (TTM)87.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.11%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBLG Yearly EPS VS EstimatesBBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800

More info and screens

Find the best growth stocksShow best growing peers

0

4. BBLG Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BBLG. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLG Price Earnings VS Forward Price EarningsBBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLG Per share dataBBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BBLG Dividend Analysis

5.1 Amount

  • No dividends for BBLG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BBLG Fundamentals: All Metrics, Ratios and Statistics

BONE BIOLOGICS CORP

NASDAQ:BBLG (3/5/2026, 8:00:02 PM)

1.22

-0.03 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners0.74%
Inst Owner Change285.55%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.20M
Revenue(TTM)N/A
Net Income(TTM)-3.95M
Analysts82.86
Price Target22.7 (1760.66%)
Short Float %2.33%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-27.15%
Min EPS beat(2)-124.81%
Max EPS beat(2)70.51%
EPS beat(4)3
Avg EPS beat(4)-3.07%
Min EPS beat(4)-124.81%
Max EPS beat(4)70.51%
EPS beat(8)6
Avg EPS beat(8)-13.37%
EPS beat(12)9
Avg EPS beat(12)-13.21%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)98.98%
EPS NY rev (3m)99.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.13%
ROE -65.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19
Quick Ratio 19
Altman-Z -16.21
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.2%
EPS Next Y63.11%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.91%
OCF growth 3YN/A
OCF growth 5YN/A

BONE BIOLOGICS CORP / BBLG FAQ

Can you provide the ChartMill fundamental rating for BONE BIOLOGICS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to BBLG.


Can you provide the valuation status for BONE BIOLOGICS CORP?

ChartMill assigns a valuation rating of 0 / 10 to BONE BIOLOGICS CORP (BBLG). This can be considered as Overvalued.


What is the profitability of BBLG stock?

BONE BIOLOGICS CORP (BBLG) has a profitability rating of 1 / 10.


What is the expected EPS growth for BONE BIOLOGICS CORP (BBLG) stock?

The Earnings per Share (EPS) of BONE BIOLOGICS CORP (BBLG) is expected to grow by 63.11% in the next year.